The ability to capture tumor biomarker changes in the course of BC progression could have consequences for further diagnostic procedures, in the context of liquid biopsies [20, 21] or conventional rebiopsies [22, 23], as well as potential therapeutic implications, especially for trials aiming for an extended indication of HER2 targeted therapies. This evidence concerns the gene ERBB2 and neoplasm.